Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.10M | -12.16M | -18.87M | -44.08M | -5.48M |
| Total Depreciation and Amortization | 3.11M | 2.99M | 2.81M | 3.04M | 3.06M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.43M | 6.35M | 4.32M | 43.74M | 2.08M |
| Change in Net Operating Assets | -5.89M | 4.19M | 9.00M | -3.48M | -3.56M |
| Cash from Operations | -4.45M | 1.37M | -2.74M | -771.00K | -3.90M |
| Capital Expenditure | -1.51M | -2.22M | -2.17M | -1.00M | -657.00K |
| Sale of Property, Plant, and Equipment | 71.00K | 3.00K | 6.00K | 195.00K | 1.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -365.00K | 9.24M | -24.92M | -1.04M | 19.58M |
| Cash from Investing | -1.80M | 7.02M | -27.08M | -1.84M | 18.92M |
| Total Debt Issued | 1.06M | 41.00K | 5.07M | 1.42M | 2.09M |
| Total Debt Repaid | -2.37M | -1.61M | -869.00K | -2.94M | -145.00K |
| Issuance of Common Stock | 1.01M | 942.00K | 21.00K | 531.00K | 137.00K |
| Repurchase of Common Stock | -264.00K | -184.00K | -239.00K | -234.00K | -142.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 1.00K | -- |
| Cash from Financing | -561.00K | -814.00K | 3.98M | -1.23M | 1.94M |
| Foreign Exchange rate Adjustments | 158.00K | 606.00K | 646.00K | 1.41M | 846.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 2.00K |
| Net Change in Cash | -6.66M | 8.18M | -25.19M | -2.43M | 17.81M |